The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies
| Autor: | Kimberly A. Shipman, J. Michael Straughn, Jenny M. Whitworth, T. Michael Numnum, Larry C. Kilgore, Kellie S. Matthews, James E. Kendrick |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
medicine.medical_specialty Neutropenia Adolescent Filgrastim Paclitaxel Genital Neoplasms Female Docetaxel Drug Administration Schedule Carboplatin Polyethylene Glycols Young Adult chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Aged Retrospective Studies Aged 80 and over Myelosuppressive Chemotherapy business.industry Obstetrics and Gynecology Middle Aged medicine.disease Recombinant Proteins Surgery Oncology chemistry Absolute neutrophil count Female Taxoids business Febrile neutropenia Pegfilgrastim medicine.drug |
| Zdroj: | Gynecologic Oncology. 112:601-604 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2008.10.025 |
| Popis: | Objective Pegfilgrastim is indicated to decrease the incidence of febrile neutropenia in patients with gynecologic malignancies who are receiving myelosuppressive chemotherapy. We sought to compare the safety and efficacy of day 1 pegfilgrastim administration to day 2 administration in patients with gynecologic malignancies. Methods We retrospectively evaluated patients receiving both chemotherapy and pegfilgrastim from June 1, 2006 to August 31, 2007 for a gynecologic malignancy. Abstracted data included patient demographics, pathology, blood counts, toxicity, and chemotherapy. After administration of chemotherapy, all patients either received 6 mg of pegfilgrastim subcutaneously on day 1 or day 2. Results 1226 administrations of pegfilgrastim in 230 patients were identified. 490 administrations of pegfilgrastim were given on day 1 compared to 736 on day 2. 70% of patients had ovarian cancer with a median age of 64 years (range 15–88). 79% of patients had stage III, IV, or recurrent disease and 67% were undergoing primary chemotherapy. The most common chemotherapy was docetaxel/carboplatin (53%) followed by paclitaxel/carboplatin (19%). The mean absolute neutrophil count (ANC) nadir was 4810/mm 3 in the day 1 cohort compared to 4212/mm 3 in the day 2 cohort ( p =.004). The incidence of Grade 3/4 neutropenia was similar in both groups (4.9% in day 1 vs. 5.7% in day 2; p =.63). Grade 3/4 febrile neutropenia was uncommon in both cohorts (0 episodes vs. 3 episodes; p =.41). Treatment delays were similar in both cohorts (5.9% vs. 7.5%; p =.35). Dose modifications were also similar in both cohorts (2.8% vs. 5.3%; p =.06). Conclusion Day 1 administration of pegfilgrastim is as effective as day 2 administration in the prevention of neutropenia in patients with gynecologic malignancies. Treatment delays and dose modifications were not increased after day 1 administration of pegfilgrastim. Administering pegfilgrastim on day 1 appears to be safe, effective, and convenient in selected patients receiving myelopsuppressive chemotherapy for gynecologic malignancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect